首页> 中文期刊> 《山东医药》 >乳腺浸润性导管癌组织中 Mfn2的表达变化及临床意义

乳腺浸润性导管癌组织中 Mfn2的表达变化及临床意义

         

摘要

Objective To observe the expression changes of mitofusin 2 ( Mfn2 ) in infiltrating ductal carcinoma of breast and to investigate its clinical significance .Methods The immunohistochemical SP method was used to assess the expression of Mfn2 in 116 cases of infiltrating ductal carcinoma of breast ( observation group ) and 10 cases of normal breast ductal epithelial tissues (control group).The relationships between Mfn2 expression and the clinicopathological parameters of breast infiltrating ductal carcinoma patients were analyzed .Results The positive expression rates of Mfn 2 in the obser-vation and control groups were 44.82%(52/116) and 90.00%(9/10), respectively (all P<0.05).The Mfn2 expres-sion was related with lymph node metastasis, histological grade, TNM staging, estrogen receptor, progesterone receptor and epidermal growth factor receptor-2 of breast infiltrating ductal carcinoma (all P<0.05).Conclusion The Mfn2 expres-sion is decreased in the breast infiltrating ductal carcinoma tissues , which may play an important role in the occurrence and development of infiltrating ductal carcinoma of breast.%目的:观察乳腺浸润性导管癌组织中线粒体融合蛋白2(Mfn2)的表达变化,并探讨其临床意义。方法采用免疫组化法检测116例份乳腺浸润性导管癌组织(观察组)、10例份正常乳腺导管上皮组织(对照组) Mfn2,分析Mfn2表达与乳腺浸润性导管癌临床病理参数的相关性。结果观察组及对照组Mfn2阳性率分别为44.82%(52/116)、90.00%(9/10),两组比较,P<0.05。 Mfn2表达与乳腺浸润性导管癌淋巴结转移、组织学分级、TNM分期、雌激素受体、孕激素受体、人表皮生长因子受体-2有关(P均<0.05)。结论乳腺浸润性导管癌组织中Mfn2的表达降低,其可能在乳腺浸润性导管癌的发生、发展过程中起作用。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号